FDA approves Bayer's asundexian as first-in-class factor XIa inhibitor for stroke prevention
The FDA approved asundexian (Sunharbo), a novel blood thinner from Bayer, to reduce the risk of recurrent stroke in adults, marking the first approval in the factor XIa inhibitor class.
